Clinuvel Pharmaceuticals Ltd CUVL
Clinuvel Pharmaceuticals Ltd (Nasdaq: CUVL) is a dermatology drug developer. Its lead program, SCENESSE (afamelanotide 16mg), is in Phase 2 for Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP); vitiligo (with NB-UVB) under study in CUV105. Its next catalyst on record is SCENESSE + NB-UVB, CUV105 vitiligo study: Top line results (December 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SCENESSE + NB-UVB, CUV105 vitiligo study — Top line results (December 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SCENESSE (afamelanotide 16mg) | Phototoxicity prevention in adult EPP | protein/peptide | Approved |
| SCENESSE + NB-UVB (CUV105 study) | Vitiligo | protein/peptide | Phase 2 |
| ZEROKIN single-use subcutaneous administration device | — | device-combination | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.